BCR up +0.26% percent right now. $BCR High is at 1
Post# of 102775
Posted On: 11/11/2014 4:19:00 PM
BCR up +0.26% percent right now. $BCR High is at 164.67 and the Low 163.03 with current volume of 137,996.
Recent News posted below.
BCR C.R. Bard Recent Headline News
Boston Scientific Shows Strength on Core Market Stabilization - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 28 mins ago
On Nov 7, 2014, we issued an updated research report on leading medical devices company Boston Scientific Corporation (BSX).
BSX: 13.41 (-0.04), ICUI: 80.87 (+9.06), BCR: 164.27 (+0.40), ABAX: 53.50 (+0.56)
Henry Schein Tops Q3 Earnings, Revenues; Shares Rally - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 10:30AM CST
Henry Schein's (HSIC) share price jumped 6.1% to eventually close at $129.62 yesterday.
ABC: 87.93 (+0.22), BCR: 164.27 (+0.40), BRLI: 28.57 (-0.23), HSIC: 129.47 (-0.15)
Steris Gains on Q2 Earnings and Revenue Beat; EPS View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Following the earnings release, Steris' (STE) share price rose 1.9% to eventually close at $63.64 yesterday.
ABC: 87.93 (+0.22), BCR: 164.27 (+0.40), BRLI: 28.57 (-0.23), STE: 64.49 (+0.85)
CR Bard Earnings Hindsight: Up 9.7% in Last 19 Days (BCR)
Comtex SmarTrend(R) - Mon Nov 10, 10:11AM CST
When CR Bard (NYSE:BCR) reported earnings 19 days ago on October 22nd, 2014, analysts, on average, expected the company to report earnings of $2.10 on sales of $819.1 million. CR Bard actually reported earnings of $2.15 per share on sales of $830.0 million, beating EPS estimates by $0.05 and beating revenue estimates by $10.9 million. Shares of CR Bard have climbed from $147.98 to $162.38, representing a gain of 9.7% since the company reported earnings 19 days ago.
BCR: 164.27 (+0.40)
CareFusion Q1 Earnings, Revenues Rise and Beat Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:30AM CST
CareFusion Corporation (CFN) now expects adjusted earnings to increase in the range of $2.80-$2.95 per share, higher than the earlier band of $2.60-$2.75 per share.
BDX: 128.76 (+0.46), BCR: 164.27 (+0.40), BAX: 70.76 (+0.13), CFN: 57.48 (-0.04)
Bard to Present at the Stifel Healthcare Conference
Business Wire - Wed Nov 05, 12:00PM CST
C. R. Bard, Inc. (NYSE:BCR) today announced that it will present at the Stifel Healthcare Conference in New York City on November 19, 2014. Christopher S. Holland, senior vice president and chief financial officer, will discuss the company in a presentation scheduled to begin at 10:55 AM Eastern Standard Time.
BCR: 164.27 (+0.40)
Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific
PR Newswire - Wed Nov 05, 7:50AM CST
Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.
BSX: 13.41 (-0.04), BCR: 164.27 (+0.40), INCY: 71.06 (+0.10), MYL: 53.51 (-0.44), AEGR: 21.56 (-0.01)
Tracking Yacktman Asset Management Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Wed Nov 05, 5:56AM CST
BDX: 128.76 (+0.46), CHRW: 71.75 (-0.42), CLX: 101.35 (-0.32), SYY: 38.52 (-0.13), XOM: 96.41 (+0.13), WMT: 79.01 (-0.43), PDCO: 44.27 (+0.12), PEP: 96.70 (-0.27), JNJ: 108.91 (+0.09), FOX: 33.39 (+0.10), EBAY: 54.21 (+0.32), FOXA: 34.93 (+0.19), MSFT: 48.87 (-0.02), NWS: 14.92 (-0.02), BK: 39.45 (-0.05), CSCO: 25.15 (unch), SYK: 88.68 (+0.24), KO: 42.51 (+0.12), AVP: 10.46 (-0.03), BCR: 164.27 (+0.40), STT: 77.69 (-0.43), COP: 71.75 (+0.15), WFC: 53.58 (-0.25), WLP: 126.62 (+1.12), ORCL: 40.47 (+0.02), USB: 44.03 (+0.10), SIAL: 135.89 (+0.08), MRK: 59.37 (+0.56), PG: 89.67 (+0.22), VIAB: 69.52 (-0.57), CMCSA: 52.96 (+0.01)
Covidien to Sell Stellarex DCB to Spectranetics for $30M - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 5:07PM CST
Divesture of Covidien plc's (COV) Stellarex DCB is subject to the approval of the Federal Trade Commission and other regulatory agencies, as well as closure of the Medtronic-Covidien merger, which is slated to complete by early 2015.
BCR: 164.27 (+0.40), MDT: 69.00 (+0.29), GWPH: 74.77 (+0.82), COV: 93.71 (+0.07)
November Stock Considerations
Divhut - at Seeking Alpha - Mon Nov 03, 9:02PM CST
As the month of November begins, I look at my portfolio holdings and wonder where I’d like to deploy my cash. This is the first month where I don’t really have a clear conviction of where I’d like to invest as the market has reached...
BMO: 71.73 (+0.25), BDX: 128.76 (+0.46), BCR: 164.27 (+0.40), TD: 49.83 (+0.34), RY: 72.18 (+0.55), VFC: 70.52 (-0.10), GWW: 246.31 (-2.46), UL: 40.74 (+0.41), CM: 91.45 (+0.42), BMS: 39.10 (-0.20), BNS: 60.39 (+0.49)
Insider Trading Alert - BCR, CYS And MMM Traded By Insiders
at The Street - Thu Oct 30, 9:45AM CDT
Stocks with insider trader activity include BCR, CYS and MMM
MMM: 157.11 (-0.55), BCR: 164.27 (+0.40), CYS: 9.02 (+0.02)
CR Bard Rises 1.08% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Oct 27, 5:12PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $156.48 to a high of $158.98. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $157.84 on volume of 874,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BCR: 164.27 (+0.40)
CR Bard Set to Possibly Pullback After Yesterday's Rally of 1.08%
Comtex SmarTrend(R) - Mon Oct 27, 5:12PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $156.48 to a high of $158.98. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $157.84 on volume of 874,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BCR: 164.27 (+0.40)
FDA clears St. Jude ablation catheter
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 10:41AM CDT
BSX: 13.41 (-0.04), ABT: 44.25 (+0.16), JNJ: 108.91 (+0.09), BCR: 164.27 (+0.40), MDT: 69.00 (+0.29), HNSN: 0.68 (-0.07), STJ: 65.79 (+0.09)
CR Bard Beats Q3 Earnings and Revenues, '14 View Raised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 7:50AM CDT
For 2014, CR Bard Inc. (BCR) increased its adjusted earnings per share guidance to the band of $ 8.34-$8.38 from the prior range of $8.25-$8.35.
BCR: 164.27 (+0.40), CAH: 79.60 (+0.51), HSIC: 129.47 (-0.15), COO: 160.03 (-0.39)
C. R. Bard's (BCR) CEO Timothy Ring on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 22, 9:21PM CDT
BCR: 164.27 (+0.40)
C. R. Bard (BCR) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Oct 22, 3:55PM CDT
BCR: 164.27 (+0.40)
C.R. Bard Q3 revenues up 9%
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 3:32PM CDT
BCR: 164.27 (+0.40)
C. R. Bard beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 3:12PM CDT
BCR: 164.27 (+0.40)
Bard Announces Third Quarter Results
Business Wire - Wed Oct 22, 3:06PM CDT
C. R. Bard, Inc. (NYSE:BCR) today reported 2014 third quarter financial results. Third quarter 2014 net sales were $830.0 million, an increase of 9 percent over the prior-year period on both an as reported and constant currency basis.
BCR: 164.27 (+0.40)
Recent News posted below.
BCR C.R. Bard Recent Headline News
Boston Scientific Shows Strength on Core Market Stabilization - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 28 mins ago
On Nov 7, 2014, we issued an updated research report on leading medical devices company Boston Scientific Corporation (BSX).
BSX: 13.41 (-0.04), ICUI: 80.87 (+9.06), BCR: 164.27 (+0.40), ABAX: 53.50 (+0.56)
Henry Schein Tops Q3 Earnings, Revenues; Shares Rally - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 10:30AM CST
Henry Schein's (HSIC) share price jumped 6.1% to eventually close at $129.62 yesterday.
ABC: 87.93 (+0.22), BCR: 164.27 (+0.40), BRLI: 28.57 (-0.23), HSIC: 129.47 (-0.15)
Steris Gains on Q2 Earnings and Revenue Beat; EPS View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Following the earnings release, Steris' (STE) share price rose 1.9% to eventually close at $63.64 yesterday.
ABC: 87.93 (+0.22), BCR: 164.27 (+0.40), BRLI: 28.57 (-0.23), STE: 64.49 (+0.85)
CR Bard Earnings Hindsight: Up 9.7% in Last 19 Days (BCR)
Comtex SmarTrend(R) - Mon Nov 10, 10:11AM CST
When CR Bard (NYSE:BCR) reported earnings 19 days ago on October 22nd, 2014, analysts, on average, expected the company to report earnings of $2.10 on sales of $819.1 million. CR Bard actually reported earnings of $2.15 per share on sales of $830.0 million, beating EPS estimates by $0.05 and beating revenue estimates by $10.9 million. Shares of CR Bard have climbed from $147.98 to $162.38, representing a gain of 9.7% since the company reported earnings 19 days ago.
BCR: 164.27 (+0.40)
CareFusion Q1 Earnings, Revenues Rise and Beat Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:30AM CST
CareFusion Corporation (CFN) now expects adjusted earnings to increase in the range of $2.80-$2.95 per share, higher than the earlier band of $2.60-$2.75 per share.
BDX: 128.76 (+0.46), BCR: 164.27 (+0.40), BAX: 70.76 (+0.13), CFN: 57.48 (-0.04)
Bard to Present at the Stifel Healthcare Conference
Business Wire - Wed Nov 05, 12:00PM CST
C. R. Bard, Inc. (NYSE:BCR) today announced that it will present at the Stifel Healthcare Conference in New York City on November 19, 2014. Christopher S. Holland, senior vice president and chief financial officer, will discuss the company in a presentation scheduled to begin at 10:55 AM Eastern Standard Time.
BCR: 164.27 (+0.40)
Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific
PR Newswire - Wed Nov 05, 7:50AM CST
Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.
BSX: 13.41 (-0.04), BCR: 164.27 (+0.40), INCY: 71.06 (+0.10), MYL: 53.51 (-0.44), AEGR: 21.56 (-0.01)
Tracking Yacktman Asset Management Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Wed Nov 05, 5:56AM CST
BDX: 128.76 (+0.46), CHRW: 71.75 (-0.42), CLX: 101.35 (-0.32), SYY: 38.52 (-0.13), XOM: 96.41 (+0.13), WMT: 79.01 (-0.43), PDCO: 44.27 (+0.12), PEP: 96.70 (-0.27), JNJ: 108.91 (+0.09), FOX: 33.39 (+0.10), EBAY: 54.21 (+0.32), FOXA: 34.93 (+0.19), MSFT: 48.87 (-0.02), NWS: 14.92 (-0.02), BK: 39.45 (-0.05), CSCO: 25.15 (unch), SYK: 88.68 (+0.24), KO: 42.51 (+0.12), AVP: 10.46 (-0.03), BCR: 164.27 (+0.40), STT: 77.69 (-0.43), COP: 71.75 (+0.15), WFC: 53.58 (-0.25), WLP: 126.62 (+1.12), ORCL: 40.47 (+0.02), USB: 44.03 (+0.10), SIAL: 135.89 (+0.08), MRK: 59.37 (+0.56), PG: 89.67 (+0.22), VIAB: 69.52 (-0.57), CMCSA: 52.96 (+0.01)
Covidien to Sell Stellarex DCB to Spectranetics for $30M - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 5:07PM CST
Divesture of Covidien plc's (COV) Stellarex DCB is subject to the approval of the Federal Trade Commission and other regulatory agencies, as well as closure of the Medtronic-Covidien merger, which is slated to complete by early 2015.
BCR: 164.27 (+0.40), MDT: 69.00 (+0.29), GWPH: 74.77 (+0.82), COV: 93.71 (+0.07)
November Stock Considerations
Divhut - at Seeking Alpha - Mon Nov 03, 9:02PM CST
As the month of November begins, I look at my portfolio holdings and wonder where I’d like to deploy my cash. This is the first month where I don’t really have a clear conviction of where I’d like to invest as the market has reached...
BMO: 71.73 (+0.25), BDX: 128.76 (+0.46), BCR: 164.27 (+0.40), TD: 49.83 (+0.34), RY: 72.18 (+0.55), VFC: 70.52 (-0.10), GWW: 246.31 (-2.46), UL: 40.74 (+0.41), CM: 91.45 (+0.42), BMS: 39.10 (-0.20), BNS: 60.39 (+0.49)
Insider Trading Alert - BCR, CYS And MMM Traded By Insiders
at The Street - Thu Oct 30, 9:45AM CDT
Stocks with insider trader activity include BCR, CYS and MMM
MMM: 157.11 (-0.55), BCR: 164.27 (+0.40), CYS: 9.02 (+0.02)
CR Bard Rises 1.08% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Oct 27, 5:12PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $156.48 to a high of $158.98. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $157.84 on volume of 874,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BCR: 164.27 (+0.40)
CR Bard Set to Possibly Pullback After Yesterday's Rally of 1.08%
Comtex SmarTrend(R) - Mon Oct 27, 5:12PM CDT
CR Bard (NYSE:BCR) traded in a range yesterday that spanned from a low of $156.48 to a high of $158.98. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $157.84 on volume of 874,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BCR: 164.27 (+0.40)
FDA clears St. Jude ablation catheter
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 10:41AM CDT
BSX: 13.41 (-0.04), ABT: 44.25 (+0.16), JNJ: 108.91 (+0.09), BCR: 164.27 (+0.40), MDT: 69.00 (+0.29), HNSN: 0.68 (-0.07), STJ: 65.79 (+0.09)
CR Bard Beats Q3 Earnings and Revenues, '14 View Raised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 7:50AM CDT
For 2014, CR Bard Inc. (BCR) increased its adjusted earnings per share guidance to the band of $ 8.34-$8.38 from the prior range of $8.25-$8.35.
BCR: 164.27 (+0.40), CAH: 79.60 (+0.51), HSIC: 129.47 (-0.15), COO: 160.03 (-0.39)
C. R. Bard's (BCR) CEO Timothy Ring on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 22, 9:21PM CDT
BCR: 164.27 (+0.40)
C. R. Bard (BCR) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Oct 22, 3:55PM CDT
BCR: 164.27 (+0.40)
C.R. Bard Q3 revenues up 9%
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 3:32PM CDT
BCR: 164.27 (+0.40)
C. R. Bard beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 3:12PM CDT
BCR: 164.27 (+0.40)
Bard Announces Third Quarter Results
Business Wire - Wed Oct 22, 3:06PM CDT
C. R. Bard, Inc. (NYSE:BCR) today reported 2014 third quarter financial results. Third quarter 2014 net sales were $830.0 million, an increase of 9 percent over the prior-year period on both an as reported and constant currency basis.
BCR: 164.27 (+0.40)
(0)
(0)